ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2705

Inhibition Of Microrna-155 Ameliorated Experimental Fibrosis By Suppressing Wnt and Akt Pathways

Qingran Yan1, Qiong Fu1, Jie Chen1, Xinfang Huang1, Nan Shen2,3 and Chunde Bao1, 1Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 2Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 3Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: MicroRNA and scleroderma

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis

Session Type: Abstract Submissions (ACR)

Background/Purpose: MicroRNA-155 plays a critical role in various physiological and pathological processes including cell proliferation and migration, epithelial- mesenchymal transition, as well as inflammation. Previous research found that miR-155 could promote the development of murine pulmonary fibrosis. The aim of this study was to evaluate the role of miR-155 in a bleomycin induced mouse model of systemic sclerosis (SSc) and to investigate the potential mechanisms involved.

Methods: miR-155 knock-out (KO) C57BL/6 and background controlled mice were given bleomycin subcutaneously every other day for 21days to induce experimental fibrosis. Dermal thickness and collagen deposition were determined histologically by Sirius red dying. Tissue fibroblast number was measured through α-smooth muscle actin (α-SMA) staining by immunohistochemistry. For in vitro study, primary murine skin fibroblasts were cultured and stimulated with TGF-β.  siRNA was applied to  inhibit miR-155 expression. Real-time PCR was used to compare collagen synthesis and activation marker expressions in miR-155 knockdown fibroblasts with controls. Collagen release was analyzed by Sircol assay. Major TGF-β induced profibrotic pathways were analyzed by Western Blot. Targets of miR-155 were predicted by bio-informatics and were confirmed by using dual luciferase report assay and Western blot.

Results: The expression level of miR-155 was significantly elevated in mice injected with bleomycin, as well as in fibroblasts stimulated by TGF-β. Compared with control mice, miR-155 KO mice displayed significantly less fibrosis in both skins and lungs, as well as less number of activated fibroblasts in situ. Consistent with the in vivo findings, miR-155-knockdown primary fibroblasts showed significantly reduced collagen synthesis and lower activation markers (fibronectin and α-SMA) upon TGF-β stimulation. Analysis of major TGF-β downstream pathways including Smad2/3, JNK, ERK, Wnt and Akt revealed that the activation of Wnt and Akt pathway were notably suppressed in miR-155-knockdown fibroblasts. These two pathways were also attenuated in the skin of miR-155 KO mice injected with bleomycin. Further bio-informatics and literature research suggested that miR-155 could directly target casein kinase I (CK-1) and Src homology 2-containing inositol phosphatase-1 (SHIP-1), which are negative regulators of Wnt and Akt pathway, respectively.  We found miR-155 inhibition would result in an increased level of these two proteins in primary fibroblast.  Further studies using dual luciferase reporter assay confirmed the direct interaction between miR-155 and 3’-UTR of CK-1 and SHIP-1. 

Conclusion: Inhibition of miR-155 could ameliorate experimental fibrosis in a bleomycin induced SSc mouse model. miR-155 modulates profibrotic Wnt and Akt pathway by directly targeting CK-1 and SHIP-1, respectively. miR-155 is a potential target for therapeutic intervention in SSc.


Disclosure:

Q. Yan,
None;

Q. Fu,
None;

J. Chen,
None;

X. Huang,
None;

N. Shen,
None;

C. Bao,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-microrna-155-ameliorated-experimental-fibrosis-by-suppressing-wnt-and-akt-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology